13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001381843
Total reported value
$371.7M
$371.7M
44 檔
16.2%
The Q1 2024 SEC filing reveals that Atle Fund Management AB held a total portfolio value of $371.7M, covering 44 public equity positions.
During Q1 2024, Atle Fund Management AB's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including MRK, LLY, UNH) accounted for 16.2% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MRK | Merck & Co. Inc. | Stock-Healthcare | 10.74% | -0.85% | +103.64% | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 9.84% | +0.95% | +31.46% | |
| 3 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 6.94% | -0.90% | EXIT | |
| 4 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 5.37% | -0.91% | +33.04% | |
| 5 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.65% | +0.77% | +244.61% | |
| 6 | HRMY | Harmony Biosciences Holdings | Stock-Other | 3.47% | — | +17.24% | |
| 7 | SYK | Stryker CORP | Stock-Healthcare | 3.30% | -0.53% | +18.37% | |
| 8 | AMGN | Amgen Inc | Stock-Healthcare | 3.27% | -2.81% | EXIT | |
| 9 | ABBV | Abbvie Inc | Stock-Healthcare | 3.25% | +1.00% | +38.45% | |
| 10 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.23% | -1.18% | +19.43% | |
| 11 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 3.16% | — | +35.54% | |
| 12 | COR | Cencora Inc | Stock-Healthcare | 3.02% | +0.24% | -47.52% | |
| 13 | MOH | Molina Healthcare Inc | Stock-Healthcare | 3.00% | — | -4.00% | |
| 14 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.87% | -1.05% | +23.71% | |
| 15 | OPCH | Option Care Health Inc | Stock-Healthcare | 2.71% | — | +257.02% | |
| 16 | ELV | Elevance Health Inc | Stock-Healthcare | 2.33% | — | -22.11% | |
| 17 | GILD | Gilead Sciences Inc | Stock-Healthcare | 2.32% | -0.74% | -47.46% | |
| 18 | DXCM | Dexcom Inc | Stock-Healthcare | 2.22% | +0.45% | +45.56% | |
| 19 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.88% | +0.15% | — | |
| 20 | CAH | Cardinal Health Inc | Stock-Healthcare | 1.87% | -0.03% | -42.71% | |
| 21 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.81% | — | +417.98% | |
| 22 | ✓ | Fusion Pharmaceuticals Inc | Stock-Other | 1.80% | — | +11.07% | |
| 23 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.68% | -0.10% | +163.13% | |
| 24 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.62% | — | +422.80% | |
| 25 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.60% | — | +210.74% | |
| 26 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 1.55% | — | -2.73% | |
| 27 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.44% | -0.16% | +19.02% | |
| 28 | SWAVUSD | Shockwave Medical Inc | Stock-Other | 0.94% | — | +34.59% | |
| 29 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.91% | — | — | |
| 30 | CABA | Cabaletta Bio Inc | Stock-Other | 0.80% | — | +269.24% | |
| 31 | ACLXGBX | Arcellx Inc | Stock-Other | 0.74% | — | +53.47% | |
| 32 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.72% | +0.21% | — | |
| 33 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.71% | -1.34% | +57.77% | |
| 34 | EXK | Exact Sciences CORP | Stock-Materials | 0.68% | — | +32.60% | |
| 35 | ✓ | Merus N V | Stock-Other | 0.67% | — | — | |
| 36 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.62% | — | +48.10% | |
| 37 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.60% | — | +19.32% | |
| 38 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.58% | — | +39.83% | |
| 39 | MGNX | Macrogenics Inc | Stock-Other | 0.44% | — | — | |
| 40 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.38% | — | +58.32% | |
| 41 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.37% | — | — | |
| 42 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.32% | +0.49% | — | |
| 43 | MORFUSD | Morphic Holding Inc | Stock-Other | 0.32% | — | — | |
| 44 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.27% | — | — |
According to official SEC Form 13F filings, Atle Fund Management AB reported a total U.S. public equity portfolio value of $371.7M across 44 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2024, Atle Fund Management AB's top holdings by market value included MRK (10.7%)、LLY (9.8%)、UNH (6.9%). The largest single position, MRK, represented 10.7% of total portfolio value.
In Q1 2024, Atle Fund Management AB made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.